TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Mesoblast Limited ( (AU:MSB) ) has shared an announcement.
Mesoblast Limited announced that its product Ryoncil® has received a permanent J-Code from the United States Medicare & Medicaid Services, facilitating easier billing and reimbursement. This milestone is expected to enhance patient access to Ryoncil®, particularly for children with life-threatening steroid-refractory acute graft-versus-host disease, and improve the product’s commercialization prospects.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is a global leader in developing allogeneic cellular medicines for treating severe and life-threatening inflammatory conditions. The company’s proprietary mesenchymal lineage cell therapy technology platform targets severe inflammation by releasing anti-inflammatory factors, significantly reducing damaging inflammatory processes. Mesoblast’s Ryoncil® is the first FDA-approved mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease in pediatric patients. The company is also developing additional cell therapies for various inflammatory diseases and has established commercial partnerships in Japan, Europe, and China.
Average Trading Volume: 4,735,122
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$3.07B
See more data about MSB stock on TipRanks’ Stock Analysis page.